Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424914 · ClinicalTrials.gov registry record · NA
Global Prevalence of ATTR-CM in Participants With HFpEF
A NA study, sponsored by Pfizer.
- Terminated
- Registry status
- NA
- Development phase
- 347
- Enrollment target
NCT04424914 is a NA study that was terminated before completion, run by Pfizer. The registered enrollment target is 347 participants.
The verdict
NCT04424914, a NA study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- NA
- Development phase
- 347 participants
- Enrollment target
Study Summary
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].
Interventions
- DIAGNOSTIC_TEST Scintigraphy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2023-06-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424914
The ClinicalTrials.gov registry entry for NCT04424914 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Scintigraphy is the first listed.
NCT04424914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424914 about?
NCT04424914 is a clinical study titled "Global Prevalence of ATTR-CM in Participants With HFpEF". This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].
What is the current status of trial NCT04424914?
This trial is currently terminated. It is a NA study. The enrollment target is 347 participants. The study started on 2020-12-30. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT04424914?
The interventions under investigation include: Scintigraphy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04424914?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.